Zhang is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry, particularly in China.
Zhi Zhang
Latest news
-
Two major UK decisions announced on use of Alzheimer’s drug, lecanemab
Read more: Two major UK decisions announced on use of Alzheimer’s drug, lecanemab -
Drug trial offers hope to 200,000 people with ‘hidden’ lung condition
Read more: Drug trial offers hope to 200,000 people with ‘hidden’ lung condition -
LifeArc funds innovative rare liver disease clinical trial
Read more: LifeArc funds innovative rare liver disease clinical trial -
Charities join forces to transform treatment for children with cancer
Read more: Charities join forces to transform treatment for children with cancer -
AI software tool aims to spot early signs of dementia from brain scans during routine appointments
Read more: AI software tool aims to spot early signs of dementia from brain scans during routine appointments